Purpose: This study aimed to examine the efficiency and sustainability of pain relief produced by corneal collagen cross-linking (CXL) in eyes with bullous keratopathy (BK) and to explore the histopathological changes in the stroma by using in vivo confocal microscopy.
(CCT) in the edematous stroma, [6] [7] [8] [9] [10] [11] [12] improve visual acuity, 8 and relieve pain due to BK 10 in eyes with severe BK. However, these results are only effective for up to 3 months. Previous assessments were conducted on patients with eyes at end-stage BK that were scheduled to undergo keratoplasty. On the other hand, the efficacy of CXL in eyes with BK in a relatively early stage has not yet been assessed. We speculated that endothelial pumping would be partially effective and that the effect of CXL would be enhanced because of less accumulation of extracellular fluid. Furthermore, change in the corneal biomaterial property by CXL is facilitated in eyes with thinner corneas, 13, 14 so that dehydration of the corneal stroma after deepithelization would enhance the clinical effect of CXL and prolong pain relief. This prospective observational case study was conducted to examine the effect and sustainability of pain relief produced by CXL in BK eyes for a 1-year period and to observe the superior stroma 1 year after treatment by using in vivo confocal microscopy.
MATERIALS AND METHODS
This study was approved by the ethics committee of Miyata Eye Hospital (identifier: CS-134) and followed the tenets of the Declaration of Helsinki. Written informed consent was obtained from all patients. The study included 14 eyes of 14 consecutive patients who underwent CXL as a palliative therapy for relieving pain until transplantation surgery at Miyata Eye Hospital and were followed up for 1 year. Inclusion criteria were BK in a relatively early stage, which was defined as corneal endothelial cell density (ECD) less than 500 cell/mm 2 , no significant opacity in the corneal stroma, pain symptoms, and no need of immediate keratoplasty. Eyes with a CCT less than 450 μm (400 μm without the corneal epithelium), a history of corneal incision surgery after the incidence of BK, deficiency in corneal epithelium restoration, corneal melting, or herpetic keratitis were excluded.
The ages of the patients ranged from 52 to 98 years, and the mean age was 78.6 ± 10.9 (SD) years. The study included 5 men and 9 women. The primary causes of BK included argon laser iridotomy in 7 eyes, uveitis in 2 eyes, iridocorneal endothelial syndrome in 2 eyes, and penetrating keratoplasty, filtration surgery, and primary angle closure in 1 eye each (Table 1) .
CXL and Examinations
The epithelium of the cornea was removed in a region of 8 to 9 mm in diameter. The BK cornea was swollen due to excess absorption of fluid and the CCT was considerably thicker, so the corneal stroma was dehydrated until the CCT was reduced to 400-450 μm. After that, 0.1% riboflavin was instilled every 2 minutes for 30 minutes. The cornea in the central 8.0 mm diameter was irradiated with UV-A (a wavelength of 365 nm and a power of 3.0 mW/cm 2 instillation. An accelerated radiation protocol consisting of 5 minutes of radiation at a power of 18.0 mW/cm 2 was used for 9 of the 14 eyes (#6 onward in Table 1 ). A contact lens was used until the corneal epithelium covered the corneal surface. The postoperative regimen was 0.5% levofloxacine and 0.1% fluorometholone eye drops 4 times daily for 3 months, then gradually decreased. Neither infection nor the progress of corneal stroma opacity was observed during the observation period. Throughout the observation period, the corneal epithelium layer was stable and corneal disorders such as neuroparalytic keratitis were not observed.
The best-corrected visual acuity (BCVA), intraocular pressure (IOP), and CCT were examined before treatment and 1 week; 1, 3, and 6 months; and 1 year after treatment. The BCVA was measured using a 5-meter Snellen chart and converted to logarithm of the minimum angle of resolution (logMAR) for analysis. The IOP was measured using a noncontact tonometer (NT-4000, Nidek, Gamagori, Japan), and CCT was measured using an anterior-segment optical coherence tomographer (SS-1000, Tomey, Nagoya, Japan). The ECD was measured using noncontact specular microscopy (FA-3509, Konan, Nishinomiya, Japan). An endothelial cell image around the center of the cornea was captured, all endothelial cells within the captured image of an area of 0.24 × 0.4 mm were automatically traced, and ECD (cell/mm 2 ) was determined as described previously. 15 The intensity of pain was assessed using a scale from 0 to 10, with increments of 1, where 0 indicated a complete lack of pain and 10 indicated the most painful
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; the frequency of pain was scaled in the same manner, and 10 indicated always painful.
At 1 year after CXL, the central corneal stroma was observed using a confocal microscope (HRT3 Rostock cornea module, Heidelberg Engineering, Heidelberg, Germany) at depths of 100 and 200 μm, as demarcation lines are normally found at depths of 274-305 μm and 219-240 μm with the use of the standard and accelerated radiation protocols, respectively. 2 Microstructures in the corneal stroma were evaluated. Within the full 400 × 400 μm frame of each image, the number of keratocyte nuclei that were in focus and entirely contained within the frame was counted, and the total length of nerve fibers was measured. The densities of keratocytes (cell/mm 2 ) and nerves (mm/mm 2 ) were calculated. 16 
Statistical Analysis
Changes in the BCVA, IOP, CCT, and intensity and frequency scores of pain symptoms were examined using the Kruskal-Wallis test and then Steel-Dwass multiple comparison. A P value less than 0.05 was considered to indicate a significant difference. The results are expressed as the mean ± standard deviation, unless otherwise specified.
RESULTS
No postoperative complication such as haze and stromal scars were observed throughout the follow-up period. The BCVA, IOP, and CCT are shown in Table 2 . The BCVA did not significantly improve after treatment (P = 0.98, Kruskal-Wallis test), and IOP and CCT did not change from their preoperative levels throughout the postoperative period (P = 0.55 and 0.27, respectively). Figure 1 shows changes in the pain intensity and frequency scores. The mean pain intensity score was 5.6 ± 2.9 (range, 0-9) before treatment, and it significantly decreased after treatment (P < 0.022, Steel-Dwass multiple comparison). The pain intensity 1 week after CXL was 1.6 ± 2.4 (range, 0-8), which did not change further during the study; the score at 1 year after treatment was 1.5 ± 2.2 (range, 0-6). The frequency score showed no difference before treatment (4.6 ± 3.1) and during 3 months thereafter Data presented as mean ± standard deviation.
(P > 0.064). However, significant decreases were found at 6 and 12 months after (P < 0.026); the score at 1 year after treatment was 1.1 ± 1.6 (range, 0-5). All patients' eyes except for 1 (#13 in Table 1 ) were examined using confocal microscopy 1 year after treatment. Figure 2 shows typical images of the corneal stroma at depths of 100 and 200 μm from the corneal surface before and 12 months after treatment. Before CXL, the keratocytes and nerve fibers in the stroma appeared as bright objects (arrows in Fig. 2) , and the extracellular matrix was observed in the stroma. Postoperatively, the keratocytes and nerve fibers were rarely observed. Figures 3 and 4 show the confocal images of all eyes 1 year after CXL at depths of 100 and 200 μm, respectively. At a depth of 100 μm, the gross densities of keratocytes and nerve fibers with respect to all images were 2.4 cells/mm 2 and 0, respectively; keratocytes were found in 3 eyes (#3, 8, and 11 in Fig. 3) . At a depth of 200 μm, these gross densities were 1.4 cells/mm 2 and 0.18 mm/mm 2 , respectively; keratocytes and nerve fibers were found in 3 eyes (#8, 9, and 11 in Fig. 4 ) and 1 (#8) eye, respectively. However, the intensity and frequency of pain symptoms in the eye of patient #8 did not increase. The keratocytes proliferated slightly, but the nerve fibers rarely regenerated.
DISCUSSION
In CXL after stromal dehydration, no significant changes were observed in BCVA and CCT during 1 year of follow-up, whereas pain relief persisted after treatment. In the previous studies of CXL treatment for BK eyes, the BCVA improved 1 month after CXL but did not differ from the pretreatment BCVA at 6 months, 10 and CCT significantly decreased and persisted for 6 months after treatment 10,11 but increased later. 12 In addition, pain symptoms were significantly relieved at 1 month but recovered to pretreatment levels by 6 months. 11 The previous histopathological analysis of corneal buttons revealed that the stroma is compacted by CXL, and this compaction alters with the progression of BK. 9 The discrepancy of previous results from our results probably comes from the difference in severity of BK and the dehydration of the stroma before CXL treatment. We supposed that the differences would allow the sustainability of the pain relief with no change in CCT.
Ocular pain in BK is caused by defects in the corneal epithelium resulting from fluid accumulation in the stroma. Therefore, pain can be relieved by reducing fluid accumulation by compacting the stroma. 6, 9, 16 Alternatively, corneal sensitivity can be blocked by ablating the subbasal nerves. In the current case series, pain relief persisted for up to 1 year, whereas CCT remained constant. The subbasal nerves require 12 to 24 months to regenerate to baseline levels after interventions, as indicated by in vivo confocal microscopy observations. 17, 18 Nerve fibers were observed 1 year after CXL at the depth of 200 μm in 1 eye (#8) without an increase in the intensity and frequency of pain symptoms. In this eye, the nerve fibers were under regeneration; however, corneal sensitivity would still be blocked between the subbasal nerves and the depth of 200 μm. These findings suggest that the pain relief after CXL persisted because of the blocking of corneal sensitivity.
In vivo confocal microscopy 1 year after CXL revealed that keratocytes and nerve fibers in the anterior stroma disappeared after treatment. A study of a human eye model and patients with keratoconus demonstrated that CXL causes keratocyte apoptosis in the anterior stroma. 17, 19, 20 Jordan et al 17 also showed changes in the subbasal nerve plexus in response to CXL for keratoconus. In vivo confocal microscopic images of a representative case at depths of 100 and 200 μm before and 1 year after CXL. The keratocytes and nerve fibers in the stroma that were observed before CXL (arrows) disappeared after CXL. Confocal microscopic images of eyes 1 year after CXL at a depth of 100 μm. Nerve fibers were absent, whereas keratocytes had regenerated (arrows). Taken together with the findings of the current study, we assumed that most of the nerve could be lost after treatment, and restoring the nerve density to pretreatment levels requires 1 year or longer. Croxatto et al 20 sequentially observed patients for up to 3 years and revealed that nerves continue to regenerate after CXL and require 2-3 years to reach pre-CXL levels. Although the current study did not examine keratoconus eyes, nerve fibers were still sparse at 1 year. Hence, the slow regeneration of the stromal nerves was hypothesized to facilitate pain relief for up to 1 year. Longer-term observations are necessary to verify this speculation.
The current cases were treated using 2 kinds of CXL protocols. It has been reported that the protocols could result in difference responses in keratoconus cases. 21, 22 Differences with the use of the accelerated protocol were examined regarding CCT and intensity and frequency of pain. As shown in Table 3 , no significant difference was found (P > 0.12, Mann-Whitney U test). Although the sample sizes were too small, the results demonstrated that the use of the accelerated protocol would be comparable with the conventional protocol. We supposed that dehydration before CXL treatment would minimize the different responses. More cases are required for verifying the differences.
The current study was subject to limitations. First, the sample size (14 eyes) was not sufficient. We designed the pain relief treatment protocol for patients with BK without a plan for immediate keratoplasty, which limited the number of subjects.
Although the above findings demonstrate that CXL effectively relieves pain in BK for up to 1 year owing to the slow regeneration of nerves in the stroma, these findings need to be confirmed in a larger patient cohort. Next, the severity of BK was not quantitatively assessed. The durations of pain relief did not coincide with previous reports, [9] [10] [11] [12] which could result from the difference in BK severity. However, the qualitative assessment of BK has not yet been standardized. Corneal opacity and endothelial pumping dysfunction need to be quantitatively scaled to improve the precision of analysis. Confocal microscope observations were limited in the central stroma and the images at 2 depths were analyzed. The effect of CXL in a BK stroma would be less and not uniform as observed after CXL of the keratoconus cases. It was anticipated that the effect in the peripheral area would alter with edematous conditions of surrounding stroma. Although uniformity was not confirmed, confocal microscopy was examined at the central area only. The current IOP values could be affected by CCT 23 and corneal biomechanical properties. 24 As the CCT did not change before and after CXL, the CCT would have less influence on IOP measurements. However, the effect of change in the biomechanical properties by CXL was not known. The use of IOP measurement compensating for the corneal biomechanical properties would be better for more precise analysis. 24 In conclusion, CXL for BK with no significant stromal opacity effectively relieved pain for 1 year. This palliative treatment would be helpful in retaining quality of vision in BK eyes until the need for surgical treatment. In vivo confocal microscopy observations demonstrated that the sustainability of pain relief was because of the slow regeneration of nerves in the stroma. 
